Diabetic Ketoacidosis

Am Fam Physician. 2005 May 1;71(9):1705-1714.

  Patient Information Handout

  Related Editorial

  Related Article

A diagnosis of diabetic ketoacidosis requires the patient’s plasma glucose concentration to be above 250 mg per dL (although it usually is much higher), the pH level to be less than 7.30, and the bicarbonate level to be 18 mEq per L or less. Beta-hydroxybutyrate is a better measurement of the degree of ketosis than serum ketones. Intravenous insulin and fluid replacement are the mainstays of therapy, with careful monitoring of potassium levels. Phosphorous and magnesium also may need to be replaced. Bicarbonate therapy rarely is needed. Infection, insulin omission, and other problems that may have precipitated ketoacidosis should be treated. Myocardial infarction is a precipitating cause of diabetic ketoacidosis that is especially important to look for in older patients with diabetes. Cerebral edema is a major complication that occurs primarily in children. Education to prevent recurrence should be offered to all patients, including how to manage sick days and when to call a physician.

Many patients with diabetes die from diabetic ketoacidosis (DKA) every year. DKA is caused by reduced insulin levels, decreased glucose use, and increased gluconeogenesis from elevated counter regulatory hormones, including catecholamines, glucagon, and cortisol. DKA primarily affects patients with type 1 diabetes, but also may occur in patients with type 2 diabetes, and is most often caused by omission of treatment, infection, or alcohol abuse.1 Use of a standard protocol provides consistent results in treating DKA.2 An evidence-based guideline for the management of DKA from the American Diabetes Association (ADA) is the basis for much of this article.3

Strength of Recommendations

Key clinical recommendation Label References Comments

Regular insulin by continuous intravenous infusion is preferred for moderate to severe diabetic ketoacidosis.

B

3

Although intravenous insulin infusion can be changed quickly and studies have found more rapid initial improvement in glucose and bicarbonate levels, there is no improvement in morbidity and mortality over insulin administered intramuscularly or subcutaneously.

Check beta-hydroxybutyrate rather than ketones to evaluate the degree of ketosis.

B

25

Beta-hydroxybutyrate is the main metabolic product in ketoacidosis. Levels correlate better with changes in arterial pH and blood bicarbonate levels than ketones, and were found to lead to better outcomes in one study of children.

Bicarbonate therapy should not be given to adult patients with a pH level of 7.0 or greater.

B

34,35,37

No studies have found improved outcomes beyond slight increases in serum pH levels after bicarbonate has been administered. A few studies suggest possible harms.

Gradual correction of glucose and osmolality and careful use of isotonic or hypotonic saline will reduce the risk of cerebral edema.

C

3

Cerebral edema is less common in adults than in children, and there are no studies in adults to report.

Phosphate should not be given routinely.

B

38,39,40

Low phosphate levels can cause problems, but phosphate does not need to be given routinely.


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series. See page 1635 for more information.

Strength of Recommendations

View Table

Strength of Recommendations

Key clinical recommendation Label References Comments

Regular insulin by continuous intravenous infusion is preferred for moderate to severe diabetic ketoacidosis.

B

3

Although intravenous insulin infusion can be changed quickly and studies have found more rapid initial improvement in glucose and bicarbonate levels, there is no improvement in morbidity and mortality over insulin administered intramuscularly or subcutaneously.

Check beta-hydroxybutyrate rather than ketones to evaluate the degree of ketosis.

B

25

Beta-hydroxybutyrate is the main metabolic product in ketoacidosis. Levels correlate better with changes in arterial pH and blood bicarbonate levels than ketones, and were found to lead to better outcomes in one study of children.

Bicarbonate therapy should not be given to adult patients with a pH level of 7.0 or greater.

B

34,35,37

No studies have found improved outcomes beyond slight increases in serum pH levels after bicarbonate has been administered. A few studies suggest possible harms.

Gradual correction of glucose and osmolality and careful use of isotonic or hypotonic saline will reduce the risk of cerebral edema.

C

3

Cerebral edema is less common in adults than in children, and there are no studies in adults to report.

Phosphate should not be given routinely.

B

38,39,40

Low phosphate levels can cause problems, but phosphate does not need to be given routinely.


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series. See page 1635 for more information.

Initial Evaluation

Initial evaluation of patients with DKA includes diagnosis and treatment of precipitating factors (Table 1418). The most common precipitating factor is infection, followed by noncompliance with insulin therapy.3 While insulin pump therapy has been implicated as a risk factor for DKA in the past, most recent studies show that with proper education and practice using the pump, the frequency of DKA is the same for patients on pump and injection therapy.19

TABLE 1

Causes of Diabetic Ketoacidosis

Common causes by frequency Other causes Selected drugs that may contribute to diabetic ketoacidosis

Infection, particularly pneumonia, urinary tract infection, and sepsis4 Inadequate insulin treatment or noncompliance4 New-onset diabetes4 Cardiovascular disease, particularly myocardial infarction5

Acanthosis nigricans6 Acromegaly7 Arterial thrombosis, including mesenteric and iliac5 Cerebrovascular accident5 Hemochromatosis8 Hyperthyroidism9 Pancreatitis10 Pregnancy11

Atypical antipsychotic agents12 Corticosteroids13 FK50614 Glucagon15 Interferon16 Sympathomimetic agents including albuterol (Ventolin), dopamine (Intropin), dobutamine (Dobutrex), terbutaline (Bricanyl),17 and ritodrine (Yutopar)18


Information from references 4 through 18.

TABLE 1   Causes of Diabetic Ketoacidosis

View Table

TABLE 1

Causes of Diabetic Ketoacidosis

Common causes by frequency Other causes Selected drugs that may contribute to diabetic ketoacidosis

Infection, particularly pneumonia, urinary tract infection, and sepsis4 Inadequate insulin treatment or noncompliance4 New-onset diabetes4 Cardiovascular disease, particularly myocardial infarction5

Acanthosis nigricans6 Acromegaly7 Arterial thrombosis, including mesenteric and iliac5 Cerebrovascular accident5 Hemochromatosis8 Hyperthyroidism9 Pancreatitis10 Pregnancy11

Atypical antipsychotic agents12 Corticosteroids13 FK50614 Glucagon15 Interferon16 Sympathomimetic agents including albuterol (Ventolin), dopamine (Intropin), dobutamine (Dobutrex), terbutaline (Bricanyl),17 and ritodrine (Yutopar)18


Information from references 4 through 18.

DIFFERENTIAL DIAGNOSIS

Three key features of diabetic acidosis are hyperglycemia, ketosis, and acidosis. The conditions that cause these metabolic abnormalities overlap. The primary differential diagnosis for hyperglycemia is hyperosmolar hyperglycemic state (Table 23,20), which is discussed in the Stoner article21 on page 1723 of this issue. Common problems that produce ketosis include alcoholism and starvation. Metabolic states in which acidosis is predominant include lactic acidosis and ingestion of drugs such as salicylates and methanol.

Abdominal pain may be a symptom of ketoacidosis or part of the inciting cause of DKA, such as appendicitis or cholecystitis. If surgery is necessary, the timing needs to be individualized for each patient with input from a surgical consultant.

TABLE 2

Diagnostic Criteria for Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State

Mild DKA Moderate DKA Severe DKA HHS

Plasma glucose (mg per dL [mmol per L])

> 250 (13.9)

> 250

> 250

> 600 (33.3)

Arterial pH

7.25 to 7.30

7.00 to 7.24

< 7.00

> 7.30

Serum bicarbonate (mEq per L)

15 to 18

10 to < 15

< 10

> 15

Urine ketones

Positive

Positive

Positive

Small

Serum ketones

Positive

Positive

Positive

Small

Beta-hydroxybutyrate

High

High

High

Normal or elevated20

Effective serum osmolality (mOsm per kg)*

Variable

Variable

Variable

> 320

Anion gap†

> 10

> 12

> 12

Variable

Alteration in sensoria or mental obtundation

Alert

Alert/drowsy

Stupor/coma

Stupor/coma


DKA = diabetic ketoacidosis; HHS = hyperosmolar hyperglycemic state.

*—Effective serum osmolality = 2 × measured Na (mEq per L) + (glucose [mg per dL] ÷ 18).

†—Anion gap = Na+ – (Cl– + HCO3– [mEq per L]).

Adapted with permission from Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(suppl 1):S95, with additional information from reference 20.

TABLE 2   Diagnostic Criteria for Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State

View Table

TABLE 2

Diagnostic Criteria for Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State

Mild DKA Moderate DKA Severe DKA HHS

Plasma glucose (mg per dL [mmol per L])

> 250 (13.9)

> 250

> 250

> 600 (33.3)

Arterial pH

7.25 to 7.30

7.00 to 7.24

< 7.00

> 7.30

Serum bicarbonate (mEq per L)

15 to 18

10 to < 15

< 10

> 15

Urine ketones

Positive

Positive

Positive

Small

Serum ketones

Positive

Positive

Positive

Small

Beta-hydroxybutyrate

High

High

High

Normal or elevated20

Effective serum osmolality (mOsm per kg)*

Variable

Variable

Variable

> 320

Anion gap†

> 10

> 12

> 12

Variable

Alteration in sensoria or mental obtundation

Alert

Alert/drowsy

Stupor/coma

Stupor/coma


DKA = diabetic ketoacidosis; HHS = hyperosmolar hyperglycemic state.

*—Effective serum osmolality = 2 × measured Na (mEq per L) + (glucose [mg per dL] ÷ 18).

†—Anion gap = Na+ – (Cl– + HCO3– [mEq per L]).

Adapted with permission from Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(suppl 1):S95, with additional information from reference 20.

SIGNS AND SYMPTOMS

DKA can develop in less than 24 hours.3 Metabolic changes occur one and one half to two hours earlier in patients who are managed only with a short-acting insulin such as lispro (Humalog).22 Patients with DKA usually present with polyuria, polydipsia, polyphagia, weakness, and Kussmaul’s respirations. Nausea and vomiting are present in 50 to 80 percent of patients, and abdominal pain is present in about 30 percent.23 Coffee-ground emesis, usually from hemorrhagic gastritis, occurs in about 25 percent of vomiting patients.3 Often, the patient’s breath will have a fruity odor.

Body temperature usually is normal or low, even with an infection. If the patient’s temperature is elevated, infection invariably is present.23 Signs of dehydration, such as dry mucous membranes, tachycardia, and hypotension, often are found. Most patients are about 10 percent dehydrated. Consciousness ranges from alert to confused to a comatose state in less than 20 percent of patients.3

LABORATORY EVALUATION

A standard laboratory work-up is listed in Table 3.3  The severity of DKA is determined primarily by the pH level, bicarbonate level, and mental status, and not by the blood glucose measurement (Table 23,20). Although the bicarbonate level typically is low, it may be normal or high in patients with vomiting, diuretic use, or alkali ingestion. If the serum osmolality is less than 320 mOsm per kg (320 mmol per kg), etiologies other than DKA should be considered.3 Osmolality can be calculated using the formula for effective osmolality (mOsm per kg):

TABLE 3

Standard Laboratory Assessment for Patients with Diabetic Ketoacidosis

Plasma glucose

Electrolytes with calculated anion gap and effective osmolality

Phosphorous

Blood urea nitrogen and creatinine

Beta-hydroxybutyrate or serum ketones if not available

Complete urinalysis with urine ketones by dipstick

Arterial blood gas or venous pH level if not available

Complete blood count with differential

Electrocardiography

As indicated

Bacterial cultures of urine, blood, throat, or other sites of suspected infection

Chest radiography if pneumonia or cardiopulmonary disease is suspected

Magnesium if patient has signs of hypomagnesemia such as cardiac arrhythmias, is alcoholic, or is taking diuretics

A1C level may help determine whether this is an acute episode in a patient with well-controlled, undiagnosed, or poorly controlled diabetes.


Information from Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(suppl 1):S94–102.

TABLE 3   Standard Laboratory Assessment for Patients with Diabetic Ketoacidosis

View Table

TABLE 3

Standard Laboratory Assessment for Patients with Diabetic Ketoacidosis

Plasma glucose

Electrolytes with calculated anion gap and effective osmolality

Phosphorous

Blood urea nitrogen and creatinine

Beta-hydroxybutyrate or serum ketones if not available

Complete urinalysis with urine ketones by dipstick

Arterial blood gas or venous pH level if not available

Complete blood count with differential

Electrocardiography

As indicated

Bacterial cultures of urine, blood, throat, or other sites of suspected infection

Chest radiography if pneumonia or cardiopulmonary disease is suspected

Magnesium if patient has signs of hypomagnesemia such as cardiac arrhythmias, is alcoholic, or is taking diuretics

A1C level may help determine whether this is an acute episode in a patient with well-controlled, undiagnosed, or poorly controlled diabetes.


Information from Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(suppl 1):S94–102.

In this equation, Na+ is the serum sodium level. Although potassium is included in some formulas, it is not included in the formula recommended by the ADA.3 Blood urea nitrogen is not included in this measurement because urea has less osmotic activity.23

Beta-hydroxybutyrate accounts for about 75 percent of ketones24 in ketoacidosis, and when available it is preferred for monitoring DKA25 over the nitroprusside method, which only measures acetoacetate.3 A value greater than 3 mg per dL is considered abnormal. The beta-hydroxybutyrate level may not normalize during the first one to two days of treatment. Although it is not monitored routinely during treatment, the beta-hydroxybutyrate level usually is less than 1.5 mg per dL after the first 12 to 24 hours of treatment.4

Liver enzymes also are elevated frequently in patients with DKA because of unknown causes.26 If pancreatitis is suspected, it must be diagnosed clinically. In one study10 of ketoacidosis, amylase was elevated in 21 percent and lipase in 29 percent of patients. If pancreatitis is suspected, contrast-enhanced computed tomography (CT) may be useful for diagnosis in selected patients. If the patient has significant hypertriglyceridemia, it can falsely lower glucose and sodium measurements by dilution. Leukocytosis may be present in DKA without infection.

Treatment

A priority of treatment should be to protect and maintain the airway, particularly in the obtunded patient, and to treat shock if present. Patients should be monitored closely and frequently. Blood glucose should be evaluated every one to two hours until the patient is stable, and the blood urea nitrogen, serum creatinine, sodium, potassium, and bicarbonate levels should be monitored every two to six hours depending on the severity of DKA.3 Cardiac monitoring may be warranted for patients with significant electrolyte disturbances. Treatment also should be directed at the underlying cause of the DKA, including antibiotics for suspected or identified infection. Although it is important to monitor urinary output, urinary catheterization is not advised routinely.

INPATIENT VS. OUTPATIENT TREATMENT

Selected patients with mild DKA who are alert and taking fluids orally may be treated under observation and sent home without admission.3 The ADA admission guidelines are a plasma glucose concentration greater than 250 mg per dL (13.9 mmol per L) with an arterial pH level below 7.30, a serum bicarbonate level of less than 15 mEq per L, and a moderate or greater level of ketones in the serum or urine.27 Patients with severe DKA should be admitted to the intensive care unit.

FLUIDS

Fluid deficits are typically 100 mL per kg of body weight.3 Fluid replacement alone will lower blood glucose. Tracer studies have found that during the first four hours of therapy for DKA, up to 80 percent of the decline in glucose concentration may be caused by rehydration.28

Fluid guidelines are summarized on the flowchart in Figure 1.3 When giving fluids, the average rate of change in effective serum osmolality ideally should not be more than 3 mOsm per hour. Patients who are able to drink can take some or all of their fluid replacement orally. Fluid intake should be modified based on urinary output. Urinary output will decrease as the osmotic diuretic effect of hyperglycemia is reduced.

When the blood glucose level has dropped below 250 mg per dL, the patient may be given fluid with 5 percent dextrose, such as 0.45 normal saline. If dextrose is not given, further ketosis may occur.

INSULIN

An intravenous insulin drip is the current standard of care for diabetic ketoacidosis, primarily because of the more rapid onset of action. Studies29 comparing intravenous insulin with subcutaneous or intramuscular insulin have found a quicker decrease in glucose and ketone levels, but no improvement in morbidity and mortality. Insulin may be mixed in a standard concentration of 1 U per 10 mL of normal saline. Common adult rates are 5 to 7 U per hour. A standard regimen is given in Figure 1.3 When the blood glucose level is less than 250 mg per dL, the intravenous insulin rate usually is decreased, or the patient is switched to subcutaneous insulin to maintain plasma glucose in the range of 150 to 200 mg per dL (8.3 to 11.1 mmol per L) until metabolic control is achieved.

Regular insulin should be used intravenously. Lispro and aspart (NovoLog) insulin are more expensive and do not work faster than regular insulin when given intravenously. A newly published regimen is treatment of DKA with subcutaneous aspart or lispro insulin.29,30 In one study,30 patients who were medically stable after initial fluid resuscitation were treated with a loading dose of 0.3 U per kg of aspart insulin, followed by 0.1 U per kg every hour. There were no significant differences in outcomes between the aspart and intravenous insulin regimens. A similar study29 comparing subcutaneous lispro insulin in a medical ward with an intravenous insulin drip in the intensive care unit showed similar outcomes, except for a 40 percent reduction in cost for patients treated in the medical ward. Long-acting insulin normally is stopped during treatment of DKA. If the patient is on an insulin pump, it should be stopped, and the patient should be switched to an intravenous infusion.31

If an intravenous infusion pump is not available, insulin can be given intramuscularly. Insulin is absorbed more rapidly intramuscularly than if given subcutaneously.32 A regimen for intramuscular insulin is given in Figure 1.3 This regimen advises that an initial dose of insulin be given intravenously and intramuscularly. When intravenous access is unavailable, studies have found that giving the entire initial dose intramuscularly also is effective.33 If intramuscular insulin is used, it is important to use a needle that is long enough to ensure that the insulin is not given subcutaneously.

POTASSIUM

Whole body potassium deficits typically are 3 to 5 mEq per L (3 to 5 mmol per L). Acidosis increases potassium levels and glucose administered with insulin lowers them. Before treatment of DKA, the level of potassium usually is normal or elevated. Potassium should be started as soon as adequate urine output is confirmed and the potassium level is less than 5 mEq per L.3 Usually 20 to 30 mEq (20 to 30 mmol) of potassium is given for each liter of fluid replacement. If the potassium level is less than 3.3 mEq per L (3.3 mmol per L), potassium replacement should be given immediately and insulin should be started only after the potassium level is above 3.3 mEq per L.3

BICARBONATE

Studies of patients with a pH level of 6.9 or higher have found no evidence that bicarbonate is beneficial,34 and some studies have suggested bicarbonate therapy may be harmful for these patients.3537 The flowchart in Figure 13 advises giving no bicarbonate if the pH level is greater than 6.9. Because there are no studies on patients with a pH level below 6.9, giving bicarbonate as an isotonic solution still is recommended. Bicarbonate therapy lowers potassium levels; therefore, potassium needs to be monitored carefully.

Management of Adults with Diabetic Ketoacidosis

Figure 1.

Algorithm for the management of adults with diabetic ketoacidosis. (NaCl = sodium chloride; IM = intramuscular; IV = intravenous; SC = subcutaneous.)Adapted with permission from Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(suppl 1):S96.

View Large

Management of Adults with Diabetic Ketoacidosis


Figure 1.

Algorithm for the management of adults with diabetic ketoacidosis. (NaCl = sodium chloride; IM = intramuscular; IV = intravenous; SC = subcutaneous.)Adapted with permission from Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(suppl 1):S96.

Management of Adults with Diabetic Ketoacidosis


Figure 1.

Algorithm for the management of adults with diabetic ketoacidosis. (NaCl = sodium chloride; IM = intramuscular; IV = intravenous; SC = subcutaneous.)Adapted with permission from Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(suppl 1):S96.

PHOSPHATE

Although the phosphate level frequently is low in patients with DKA, good-quality studies have shown that routine phosphate replacement does not improve outcomes in DKA, and excessive replacement can lead to hypocalcemia.3,3840 If the patient’s serum phosphate level is below normal, consider giving one third to one half of the potassium may be given in the form of potassium phosphate, provided the level of serum calcium is monitored closely.3,41

MAGNESIUM

A serum deficit of 1 to 2 mEq per L (0.50 to 1 mmol per L) of magnesium usually exists. In addition to alterations in magnesium metabolism from DKA, many patients with diabetes have taken medications such as diuretics that also may lower magnesium levels. Symptoms of magnesium deficiency are difficult to recognize and overlap with symptoms caused by deficiencies of calcium, potassium, and sodium. Paresthesias, tremor, carpopedal spasm, agitation, seizures, and cardiac dysrhythmias all are reported symptoms. Checking magnesium levels and correcting low levels should be considered in patients with DKA. Patients usually are symptomatic at serum levels of 1.2 mg per dL (0.50 mmol per L) or lower.42 If the level is below normal (i.e., less than 1.8 mg per dL [0.74 mmol per L]) and symptoms are present, administration of magnesium should be considered.42

SODIUM

Whole body sodium deficits typically are 7 to 10 mEq per L (7 to 10 mmol per L). Serum sodium is falsely lowered by 1.6 mEq for every 100 mg per dL increase in blood glucose. Hyponatremia needs to be corrected only when the sodium level is still low after adjusting for this effect. For example, in a patient with a serum glucose concentration of 600 mg per dL (33.3 mmol per L) and a measured serum sodium level of 130, the true serum sodium level is 130 + (1.6 × 5) = 138. A high serum sodium level almost always indicates hypernatremic dehydration.

Complications

Common complications of DKA include hypoglycemia, hypokalemia, and recurrent hyperglycemia. These may be minimized by careful monitoring. Hyperchloremia is a common but transient finding that usually requires no special treatment.

Cerebral edema is a rare but important complication of DKA. Although it can affect adults, it is more common in young patients, occurring in 0.7 to 1.0 percent of children with DKA.3 Early signs of cerebral edema include headache, confusion, and lethargy. Papilledema, hypertension, hyperpyrexia, and diabetes insipidus also may occur. Patients typically improve mentally with initial treatment of DKA, but then suddenly worsen. Dilated ventricles may be found on CT or magnetic resonance imaging. Treatment of suspected cerebral edema should not be delayed for these tests to be completed. In more severe cases, seizures, pupillary changes, and respiratory arrest with brain-stem herniation may occur. Once severe symptoms occur, the mortality rate is greater than 70 percent, and only about 10 percent of patients recover without sequelae.3

Avoiding overhydration and limiting the rate at which the blood glucose level drops may reduce the chance of cerebral edema.3 However, some patients may present with cerebral edema before treatment is started. About 10 percent of the patients initially diagnosed with cerebral edema have other intracranial pathology such as subarachnoid hemorrhage.43 Mannitol (Osmitrol) therapy and hyperventilation have been recommended based on limited evidence.44,45

Special Situations—Young and Old Patients

The main differences in the management of children and adolescents compared with adults are the greater care in administering electrolytes, fluids, and insulin based on the weight of the patient and increased concern about high fluid rates inducing cerebral edema. A flowchart for the management of DKA in children and adolescents from the ADA guideline is shown in Figure 2.3 A growing problem is the development of type 2 diabetes in obese children. Although DKA is less common in these patients than among those with type 1 diabetes, it does occur. C-peptide levels may be helpful for determining the type of diabetes and guiding subsequent treatment. Risk factors for adolescent type 2 diabetes are hypertension and acanthosis nigricans.6

Management of Patients Younger than 20 Years with Diabetic Ketoacidosis* or Hyperosmolar Hyperglycemic State†

Figure 2.

Algorithm for the management of patients younger than 20 years with diabetic ketoacidosis* or hyperosmolar hyperglycemic state.† (NaCl = sodium chloride; IM = intramuscular; IV = intravenous; SC = subcutaneous.)Adapted with permission from Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(suppl 1):S98.

View Large

Management of Patients Younger than 20 Years with Diabetic Ketoacidosis* or Hyperosmolar Hyperglycemic State†


Figure 2.

Algorithm for the management of patients younger than 20 years with diabetic ketoacidosis* or hyperosmolar hyperglycemic state.† (NaCl = sodium chloride; IM = intramuscular; IV = intravenous; SC = subcutaneous.)Adapted with permission from Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(suppl 1):S98.

Management of Patients Younger than 20 Years with Diabetic Ketoacidosis* or Hyperosmolar Hyperglycemic State†


Figure 2.

Algorithm for the management of patients younger than 20 years with diabetic ketoacidosis* or hyperosmolar hyperglycemic state.† (NaCl = sodium chloride; IM = intramuscular; IV = intravenous; SC = subcutaneous.)Adapted with permission from Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(suppl 1):S98.

Older patients are less likely to be on insulin before developing DKA, less likely to have had a previous episode of DKA, typically require more insulin to treat the DKA, have a longer length of hospital stay, and have a higher mortality rate (22 percent for those 65 years and older versus 2 percent for those younger than 65 years).46 Causes of death include infection, thromboembolism, and myocardial infarction.47 Although concomitant diseases and high rates of morbidity need to be considered when caring for older patients with DKA, no specific treatment guidelines are available.

Transition to Standard Regimen and Prevention of Recurrence

A blood glucose concentration of less than 200 mg per dL, a bicarbonate level of 18 mEq per L or greater, and a venous pH level of greater than 7.3 indicate that the DKA has resolved.3 Typical duration of therapy is about 48 hours.3 If the patient can eat when DKA has resolved, a standard subcutaneous insulin regimen by injection or insulin pump should be started.

Intravenous insulin should continue for one to two hours after initiation of subcutaneous insulin. For patients who are unable to eat, intravenous insulin may be continued to maintain the blood glucose in a target range (i.e., 80 to 140 mg per dL [4.4 to 7.8 mmol per L]).

Prevention of another episode should be part of the treatment of DKA. Most patients with DKA will need lifetime insulin therapy after discharge from the hospital. Education about diabetes is a cornerstone of prevention that also has been found to reduce length of stay.48  Strategies for prevention are listed in Table 4.4951

TABLE 4

Strategies to Prevent Diabetic Ketoacidosis

Diabetic education

Blood glucose monitoring

Sick-day management

Home monitoring of ketones or beta-hydroxybutyrate

Supplemental short-acting insulin regimens

Easily digestible liquid diets when sick

Reducing, rather than eliminating, insulin when patients are not eating

Guidelines for when patients should seek medical attention

Case monitoring of high-risk patients

Special education for patients on pump management


Information from references 49 through 51.

TABLE 4   Strategies to Prevent Diabetic Ketoacidosis

View Table

TABLE 4

Strategies to Prevent Diabetic Ketoacidosis

Diabetic education

Blood glucose monitoring

Sick-day management

Home monitoring of ketones or beta-hydroxybutyrate

Supplemental short-acting insulin regimens

Easily digestible liquid diets when sick

Reducing, rather than eliminating, insulin when patients are not eating

Guidelines for when patients should seek medical attention

Case monitoring of high-risk patients

Special education for patients on pump management


Information from references 49 through 51.

The Author

DAVID E. TRACHTENBARG, M.D., is associate director of the Methodist Medical Center Family Practice Residency at the University of Illinois College of Medicine, Peoria, medical director of the Methodist Diabetes Care Center, Peoria, and clinical professor of family and community medicine at the University of Illinois College of Medicine, Peoria. Dr. Trachtenbarg received his medical degree from the University of Illinois College of Medicine at Chicago and completed his residency training at the Methodist Medical Center Family Practice Residency at the University of Illinois College of Medicine, Peoria.

Address correspondence to David E. Trachtenbarg, M.D., University of Illinois College of Medicine, Family Medical Center, 815 Main St., Suite C, Peoria, IL 61602 (e-mail: tracht@mmci.org). Reprints are not available from the author.

Members of various family medicine departments develop articles for “Practical Therapeutics.” This article is one in a series coordinated by the Department of Family and Community Medicine at the University of Illinois at Chicago, Rockford. Guest editor of the series is Eric Henley, M.D.

 

REFERENCES

1. Wilson C, Krakoff J, Gohdes D. Ketoacidosis in Apache Indians with non–insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:2098–100.

2. Ilag LL, Kronick S, Ernst RD, Grondin L, Alaniz C, Liu L, et al. Impact of a critical pathway on inpatient management of diabetic ketoacidosis. Diabetes Res Clin Pract. 2003;62:23–32.

3. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care. 2004;27(suppl 1):S94–102.

4. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001;24:131–53.

5. Hamblin PS, Topliss DJ, Chosich N, Lording DW, Stockigt JR. Deaths associated with diabetic ketoacidosis and hyperosmolar coma. 1973–1988. Med J Aust. 1989;151:439–44.

6. Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care. 1997;20:484–6.

7. Kopff B, Mucha S, Wolffenbuttel BH, Drzewoski J. Diabetic ketoacidosis in a patient with acromegaly. Med Sci Monit. 2001;7:142–7.

8. Pasternak DP. Hemochromatosis presenting as diabetic ketoacidosis with extreme hyperglycemia. West J Med. 1974;120:244–6.

9. Cooppan R, Kozak GP. Hyperthyroidism and diabetes mellitus. An analysis of 70 patients. Arch Intern Med. 1980;140:370–3.

10. Nair S, Yadav D, Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol. 2000;95:2795–800.

11. Inagaki T, Nishii Y, Suzuki N, Suzuki S, Koizumi Y, Aizawa T, et al. Fulminant diabetes mellitus associated with pregnancy: case reports and literature review. Endocr J. 2002;49:319–22.

12. Wilson DR, D’Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2003;59:1–6.

13. Alavi IA, Sharma BK, Pillay VK. Steroid-induced diabetic ketoacidosis. Am J Med Sci. 1971;262:15–23.

14. Toyonaga T, Kondo T, Miyamura N, Sekigami T, Sonoda K, Kodama S, et al. Sudden onset of diabetes with ketoacidosis in a patient treated with FK506/tacrolimus. Diabetes Res Clin Pract. 2002;56:13–8.

15. Tyler J, Walsh CH, Baddeley RM, Down RH. Diabetic ketoacidosis following glucagon therapy in acute pancreatitis. A case report. Ir Med J. 1977;70:488–9.

16. Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, et al. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci. 2002;47:1649–54.

17. Tibaldi JM, Lorber DL, Nerenberg A. Diabetic ketoacidosis and insulin resistance with subcutaneous terbutaline infusion: a case report. Am J Obstet Gynecol. 1990;163:509–10.

18. Schilthuis MS, Aarnoudse JG. Fetal death associated with severe ritodrine induced ketoacidosis. Lancet. 1980;1(8178):1145.

19. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002;25:593–8.

20. Kinoshita O, Masuda I, Suzuki M, Tsushima M, Nishioeda Y, Matsuyama T, et al. A case of diabetic non-ketotic hyperosmolar coma with an increase with plasma 3-hydroxybutyrate. Endocrinol Jpn. 1991;38:465–70.

21. Stoner GD. Hyperosmolar hyperglycemic state Am Fam Physician. 2005;71:1723–30.

22. Reichel A, Rietzsch H, Kohler HJ, Pfutzner A, Gudat U, Schulze J. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro. Exp Clin Endocrinol Diabetes. 1998;106:168–72.

23. Siperstein MD. Diabetic ketoacidosis and hyperosmolar coma. Endocrinol Metab Clin North Am. 1992;21:415–32.

24. Samuelsson U, Ludvigsson J. When should determination of ketonemia be recommended? Diabetes Technol Ther. 2002;4:645–50.

25. Vanelli M, Chiari G, Capuano C, Iovane B, Bernardini A, Giacalone T. The direct measurement of 3-beta-hydroxy butyrate enhances the management of diabetic ketoacidosis in children and reduces time and costs of treatment. Diabetes Nutr Metab. 2003;16:312–6.

26. Takaike H, Uchigata Y, Iwasaki N, Iwamoto Y. Transient elevation of liver transaminase after starting insulin therapy for diabetic ketosis or ketoacidosis in newly diagnosed type 1 diabetes mellitus. Diabetes Res Clin Pract. 2004;64:27–32.

27. American Diabetes Association. Hospital admission guidelines for diabetes. Diabetes Care. 2004;27(suppl 1):S103.

28. Schade DS, Eaton RP. Diabetic ketoacidosis—pathogenesis, prevention and therapy. Clin Endocrinol Metab. 1983;12:321–38.

29. Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004;117:291–6.

30. Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27:1873–8.

31. Lee SW, Im R, Magbual R. Current perspectives on the use of continuous subcutaneous insulin infusion in the acute care setting and overview of therapy. Crit Care Nurs Q. 2004;27:172–84.

32. Guerra SM, Kitabchi AE. Comparison of the effectiveness of various routes of insulin injection: insulin levels and glucose response in normal subjects. J Clin Endocrin Metab. 1976;42:869–74.

33. Soler NG, FitzGerald MG, Wright AD, Malins JM. Comparative study of different insulin regimens in management of diabetic ketoacidosis. Lancet. 1975;2(7947):1221–4.

34. Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med. 1986;105:836–40.

35. Viallon A, Zeni F, Lafond P, Venet C, Tardy B, Page Y, et al. Does bicarbonate therapy improve the management of severe diabetic ketoacidosis? Crit Care Med. 1999;27:2690–3.

36. Okuda Y, Adrogue HJ, Field JB, Nohara H, Yamashita K. Counterproductive effects of sodium bicarbonate in diabetic ketoacidosis. J Clin Endocrinol Metab. 1996;81:314–20.

37. Hale PJ, Crase J, Nattrass M. Metabolic effects of bicarbonate in the treatment of diabetic ketoacidosis. Br Med J (Clin Res Ed). 1984;289:1035–8.

38. Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab. 1983;57:177–80.

39. Keller U, Berger W. Prevention of hypophosphatemia by phosphate infusion during treatment of diabetic ketoacidosis and hyperosmolar coma. Diabetes. 1980;29:87–95.

40. Wilson HK, Keuer SP, Lea AS, Boyd AE 3d, Eknoyan G. Phosphate therapy in diabetic ketoacidosis. Arch Intern Med. 1982;142:517–20.

41. Lloyd CW, Johnson CE. Management of hypophosphatemia. Clin Pharm. 1988;7:123–8.

42. Tso EL, Barish RA. Magnesium: clinical considerations. J Emerg Med. 1992;10:735–45.

43. Edge JA. Cerebral oedema during treatment of diabetic ketoacidosis: are we any nearer finding a cause? Diabetes Metab Res Rev. 2000;16:316–24.

44. Dunger DB, Sperling MA, Acerini CL, Bohn DJ, Daneman D, Danne TP, et al. European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement on diabetic ketoacidosis in children and adolescents. Pediatrics. 2004;113:e133–40.

45. Marcin JP, Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, et al. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. J Pediatr. 2002;141:793–7.

46. Malone ML, Gennis V, Goodwin JS. Characteristics of diabetic ketoacidosis in older versus younger adults. J Am Geriatr Soc. 1992;40:1100–4.

47. Gale EA, Dornan TL, Tattersall RB. Severely uncontrolled diabetes in the over-fifties. Diabetologia. 1981;21:25–8.

48. Feddersen E, Lockwood DH. An inpatient diabetes educator’s impact on length of hospital stay. Diabetes Educ. 1994;20:125–8.

49. Brink SJ. Diabetic ketoacidosis Acta Paediatr Suppl. 1999;88:14–24.

50. Brink SJ. Diabetic ketoacidosis: prevention, treatment and complications in children and adolescents. Diabetes Nutr Metab. 1999;12:122–35.

51. Freeland BS. Diabetic ketoacidosis. Diabetes Educ. 2003;29:384–95.


Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article